{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T05:06:52Z","timestamp":1748063212114},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,6]]},"DOI":"10.7759\/cureus.44785","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T18:23:01Z","timestamp":1694024581000},"source":"Crossref","is-referenced-by-count":1,"title":["Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach"],"prefix":"10.7759","author":[{"given":"Shikha","family":"Mudgal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranoy","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bina","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnav","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalinee","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilotpal","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.08.001","article-title":"A roundtable discussion of the Breast Cancer Therapy Expert Group (BCTEG): clinical developments and practice guidance on human epidermal growth factor receptor 2 (HER2)-positive breast cancer","volume":"20","author":"Mahtani R","year":"2020","unstructured":"Mahtani R, Holmes FA, Badve S, et al.. A roundtable discussion of the Breast Cancer Therapy Expert Group (BCTEG): clinical developments and practice guidance on human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Clin Breast Cancer. 2020, 20:e251-60. 10.1016\/j.clbc.2019.08.001","journal-title":"Clin Breast Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff AC","year":"2018","unstructured":"Wolff AC, Hammond ME, Allison KH, et al.. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018, 36:2105-22. 10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-2897","article-title":"Abstract 2897: ERBB2 amplicon passenger genes: a novel class of breast cancer antigens","volume":"74","author":"Plautz GE","year":"2014","unstructured":"Plautz GE, Modi A, Wang LX. Abstract 2897: ERBB2 amplicon passenger genes: a novel class of breast cancer antigens. Cancer Res. 2014, 74:2897. 10.1158\/1538-7445.AM2014-2897","journal-title":"Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00438-018-1488-4","article-title":"Identification of the copy number variant biomarkers for breast cancer subtypes","volume":"294","author":"Pan X","year":"2019","unstructured":"Pan X, Hu X, Zhang YH, et al.. Identification of the copy number variant biomarkers for breast cancer subtypes. Mol Genet Genomics. 2019, 294:95-110. 10.1007\/s00438-018-1488-4","journal-title":"Mol Genet Genomics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01423","article-title":"The hierarchical modular structure of HER2+ breast cancer network","volume":"9","author":"Alcal\u00e1-Corona SA","year":"2018","unstructured":"Alcal\u00e1-Corona SA, Espinal-Enr\u00edquez J, de Anda-J\u00e1uregui G, Hern\u00e1ndez-Lemus E. The hierarchical modular structure of HER2+ breast cancer network. Front Physiol. 2018, 9:1423. 10.3389\/fphys.2018.01423","journal-title":"Front Physiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0841","article-title":"Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization","volume":"11","author":"Vinatzer U","year":"2005","unstructured":"Vinatzer U, Dampier B, Streubel B, et al.. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res. 2005, 11:8348-57. 10.1158\/1078-0432.CCR-05-0841","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01320","article-title":"Discovery, development, and cellular delivery of potent and selective bicyclic peptide inhibitors of Grb7 cancer target","volume":"60","author":"Watson GM","year":"2017","unstructured":"Watson GM, Kulkarni K, Sang J, et al.. Discovery, development, and cellular delivery of potent and selective bicyclic peptide inhibitors of Grb7 cancer target. J Med Chem. 2017, 60:9349-59. 10.1021\/acs.jmedchem.7b01320","journal-title":"J Med Chem"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1010-0","article-title":"GRB7 protein over-expression and clinical outcome in breast cancer","volume":"127","author":"Ramsey B","year":"2011","unstructured":"Ramsey B, Bai T, Hanlon Newell A, et al.. GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Res Treat. 2011, 127:659-69. 10.1007\/s10549-010-1010-0","journal-title":"Breast Cancer Res Treat"},{"key":"ref9","unstructured":"GRB7 protein expression summary - The Human Protein Atlas. (2023). Accessed. August 26, 2023: https:\/\/www.proteinatlas.org\/ENSG00000141738-GRB7."},{"key":"ref10","unstructured":"PGAP3 protein expression summary - The Human Protein Atlas. (2023). Accessed. August 26, 2023: https:\/\/www.proteinatlas.org\/ENSG00000161395-PGAP3."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff AC","year":"2018","unstructured":"Wolff AC, Hammond ME, Allison KH, et al.. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018, 142:1364-82. 10.5858\/arpa.2018-0902-SA","journal-title":"Arch Pathol Lab Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin X","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, M\u00fcller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011, 12:77. 10.1186\/1471-2105-12-77","journal-title":"BMC Bioinformatics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda Y","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013, 48:452-8. 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdp346","article-title":"Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer","volume":"21","author":"Nadler Y","year":"2010","unstructured":"Nadler Y, Gonz\u00e1lez AM, Camp RL, Rimm DL, Kluger HM, Kluger Y. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Ann Oncol. 2010, 21:466-73.","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S274574","article-title":"The novel circular RNA Circ-PGAP3 promotes the proliferation and invasion of triple negative breast cancer by regulating the miR-330-3p\/Myc axis","volume":"13","author":"He D","year":"2020","unstructured":"He D, Yang X, Kuang W, Huang G, Liu X, Zhang Y. The novel circular RNA Circ-PGAP3 promotes the proliferation and invasion of triple negative breast cancer by regulating the miR-330-3p\/Myc axis. Onco Targets Ther. 2020, 13:10149-59. 10.2147\/OTT.S274574","journal-title":"Onco Targets Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2015-203178","article-title":"Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics","volume":"68","author":"Elliott K","year":"2015","unstructured":"Elliott K, McQuaid S, Salto-Tellez M, Maxwell P. Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics. J Clin Pathol. 2015, 68:766-70. 10.1136\/jclinpath-2015-203178","journal-title":"J Clin Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2144\/BTN-2020-0095\/ASSET\/IMAGES\/LARGE\/FIGURE4.JPEG","article-title":"Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry","volume":"69","author":"MacNeil T","year":"2020","unstructured":"MacNeil T, Vathiotis IA, Martinez-Morilla S, Yaghoobi V, Zugazagoitia J, Liu Y, Rimm DL. Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry. BioTechniques. 2020, 69:461-8. 10.2144\/BTN-2020-0095\/ASSET\/IMAGES\/LARGE\/FIGURE4.JPEG","journal-title":"BioTechniques"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2013-0610-CP","article-title":"Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center","volume":"138","author":"Fitzgibbons PL","year":"2014","unstructured":"Fitzgibbons PL, Bradley LA, Fatheree LA, et al.. Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med. 2014, 138:1432-43. 10.5858\/arpa.2013-0610-CP","journal-title":"Arch Pathol Lab Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/path.5528","article-title":"GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma","volume":"252","author":"Gotovac JR","year":"2020","unstructured":"Gotovac JR, Liu DS, Yates MJ, et al.. GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma. J Pathol. 2020, 252:317-29. 10.1002\/path.5528","journal-title":"J Pathol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050435","article-title":"Grb7, a critical mediator of EGFR\/ErbB signaling, in cancer development and as a potential therapeutic target","volume":"8","author":"Chu PY","year":"2019","unstructured":"Chu PY, Tai YL, Shen TL. Grb7, a critical mediator of EGFR\/ErbB signaling, in cancer development and as a potential therapeutic target. Cells. 2019, 8:435. 10.3390\/cells8050435","journal-title":"Cells"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0735","article-title":"Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes","volume":"11","author":"Cobleigh MA","year":"2005","unstructured":"Cobleigh MA, Tabesh B, Bitterman P, et al.. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005, 11:8623-31. 10.1158\/1078-0432.CCR-05-0735","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/186817-detecting-human-epidermal-growth-factor-receptor-2-her2-amplification-proof-of-concept-of-an-alternative-approach","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:32Z","timestamp":1707509192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/186817-detecting-human-epidermal-growth-factor-receptor-2-her2-amplification-proof-of-concept-of-an-alternative-approach"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.44785","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}